2026-08-29T09:17:15Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/261032025-12-18T12:56:31Zcom_20.500.12105_19586com_20.500.12105_2202col_20.500.12105_19587

00925njm 22002777a 4500 dc Devesa, Ana author Ibanez, Borja author Malick, Waqas A author Tinuoye, Elizabeth O author Bustamante, Jessica author Peyra, Carlos author Rosenson, Robert S author Bhatt, Deepak L author Stone, Gregg W author Fuster, Valentin author 2023-11-28 There is growing evidence that the atherosclerotic process that leads to symptomatic cardiovascular disease (CVD) starts at an early age. In young adults, exposure to low-density lipoprotein-cholesterol and other cardiovascular risk factor (CVRF) mediators, even at levels considered within normal limits, increases the prevalence of subclinical atherosclerosis and is associated with greater risk of cardiovascular events later in life. The optimal CVRF targets to prevent CVD in asymptomatic young individuals (<40 years) are unknown. The randomized controlled PRECAD (Prevent Coronary Artery Disease) trial has been developed to assess the potential benefit of an aggressive control of CVRF in otherwise healthy young adults. The hypothesis of PRECAD is that in subjects aged 20 to 39 years without known CVD, maintaining low-density lipoprotein-cholesterol <70 mg/dL and strict control of blood pressure and glucose will prevent the onset of atherosclerosis and/or its progression. The primary endpoint will be the change in total atherosclerosis burden, a surrogate for CVD. J Am Coll Cardiol. 2023 Nov 28;82(22):2152-2162. Journal of the American College of Cardiology 37993206 https://hdl.handle.net/20.500.12105/26103 cardiovascular disease primary prevention subclinical atherosclerosis young adults Primary Prevention of Subclinical Atherosclerosis in Young Adults: JACC Review Topic of the Week.